Clinical Trials Logo

Clinical Trial Summary

This pilot clinical trial studies how well web-based coping and communication skills intervention works in improving psychological adaptation in patients with gynecological cancer. Web-based intervention, such as coping and communication skills intervention, may help doctors to get a better understanding of ways to help gynecological cancer patients cope with their cancer experience.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To examine the feasibility and acceptability of an online coping and communication skills intervention (CCI). II. To collect pilot data on the impact of online CCI on global and cancer-specific distress. OUTLINE: Patients complete 3 modules of online CCI intervention. After completion of study, patients are followed up at 2 months. ;


Study Design


Related Conditions & MeSH terms

  • Carcinoma, Ovarian Epithelial
  • Carcinosarcoma
  • Endometrial Carcinoma
  • Endometrial Neoplasms
  • Fallopian Tube Neoplasms
  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Stage 0 Fallopian Tube Cancer AJCC v7
  • Stage I Fallopian Tube Cancer AJCC v6 and v7
  • Stage I Ovarian Cancer AJCC v6 and v7
  • Stage IA Fallopian Tube Cancer AJCC v6 and v7
  • Stage IA Ovarian Cancer AJCC v6 and v7
  • Stage IB Fallopian Tube Cancer AJCC v6 and v7
  • Stage IB Ovarian Cancer AJCC v6 and v7
  • Stage IC Fallopian Tube Cancer AJCC v6 and v7
  • Stage IC Ovarian Cancer AJCC v6 and v7
  • Stage II Cervical Cancer AJCC v7
  • Stage II Fallopian Tube Cancer AJCC v6 and v7
  • Stage II Ovarian Cancer AJCC v6 and v7
  • Stage II Uterine Corpus Cancer AJCC v7
  • Stage IIA Cervical Cancer AJCC v7
  • Stage IIA Fallopian Tube Cancer AJCC v6 and v7
  • Stage IIA Ovarian Cancer AJCC V6 and v7
  • Stage IIA1 Cervical Cancer AJCC v7
  • Stage IIA2 Cervical Cancer AJCC v7
  • Stage IIB Cervical Cancer AJCC v6 and v7
  • Stage IIB Fallopian Tube Cancer AJCC v6 and v7
  • Stage IIB Ovarian Cancer AJCC v6 and v7
  • Stage IIC Fallopian Tube Cancer AJCC v6 and v7
  • Stage IIC Ovarian Cancer AJCC v6 and v7
  • Stage III Cervical Cancer AJCC v6 and v7
  • Stage III Fallopian Tube Cancer AJCC v7
  • Stage III Ovarian Cancer AJCC v6 and v7
  • Stage III Primary Peritoneal Cancer AJCC v7
  • Stage III Uterine Corpus Cancer AJCC v7
  • Stage IIIA Cervical Cancer AJCC v6 and v7
  • Stage IIIA Fallopian Tube Cancer AJCC v7
  • Stage IIIA Ovarian Cancer AJCC v6 and v7
  • Stage IIIA Primary Peritoneal Cancer AJCC v7
  • Stage IIIA Uterine Corpus Cancer AJCC v7
  • Stage IIIB Cervical Cancer AJCC v6 and v7
  • Stage IIIB Fallopian Tube Cancer AJCC v7
  • Stage IIIB Ovarian Cancer AJCC v6 and v7
  • Stage IIIB Primary Peritoneal Cancer AJCC v7
  • Stage IIIB Uterine Corpus Cancer AJCC v7
  • Stage IIIC Fallopian Tube Cancer AJCC v7
  • Stage IIIC Ovarian Cancer AJCC v6 and v7
  • Stage IIIC Primary Peritoneal Cancer AJCC v7
  • Stage IIIC Uterine Corpus Cancer AJCC v7
  • Stage IIIC1 Uterine Corpus Cancer AJCC v7
  • Stage IIIC2 Uterine Corpus Cancer AJCC v7
  • Stage IV Cervical Cancer AJCC v6 and v7
  • Stage IV Fallopian Tube Cancer AJCC v6 and v7
  • Stage IV Ovarian Cancer AJCC v6 and v7
  • Stage IV Primary Peritoneal Cancer AJCC v7
  • Stage IV Uterine Corpus Cancer AJCC v7
  • Stage IVA Cervical Cancer AJCC v6 and v7
  • Stage IVA Uterine Corpus Cancer AJCC v7
  • Stage IVB Cervical Cancer AJCC v6 and v7
  • Stage IVB Uterine Corpus Cancer AJCC v7
  • Uterine Carcinosarcoma
  • Uterine Cervical Neoplasms
  • Uterine Corpus Sarcoma

NCT number NCT03902379
Study type Interventional
Source Rutgers, The State University of New Jersey
Contact
Status Withdrawn
Phase N/A
Start date July 27, 2016
Completion date May 31, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting NCT05036681 - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma Phase 2
Completed NCT00729586 - Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer Phase 2
Completed NCT00756847 - Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors Phase 1
Completed NCT02983279 - Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer N/A
Completed NCT02017353 - Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma Phase 2
Completed NCT00997373 - Letrozole as a Treatment of Endometrial Cancer N/A
Recruiting NCT04851119 - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Phase 1/Phase 2
Recruiting NCT04576104 - Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer Phase 2
Not yet recruiting NCT06102252 - Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as an Adjuvant Treatment in Endometrial Carcinoma N/A
Active, not recruiting NCT02598219 - Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence. Phase 3
Recruiting NCT04159155 - A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer Phase 2/Phase 3
Recruiting NCT05139368 - Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer N/A
Recruiting NCT02611024 - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Phase 1/Phase 2
Completed NCT03849469 - A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors Phase 1
Active, not recruiting NCT03917381 - GEN1046 Safety Trial in Patients With Malignant Solid Tumors Phase 1/Phase 2
Completed NCT03372720 - Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors N/A
Not yet recruiting NCT06253494 - Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer Phase 1/Phase 2
Recruiting NCT05316467 - Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma Phase 2/Phase 3
Active, not recruiting NCT03752398 - A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) Phase 1